The flow of money to startups trying to leverage CRISPR/Cas-9 technology for clinical purposes apparently is limitless. 

Intellia Therapeutics this week said that it raised $70 million in a Series B funding round that drew some heavyweight investors, including OrbiMed HealthCare Fund Management, Fidelity Management and Research, Janus Capital Management, and others. Founding investors Atlas Venture and Novartis also participated in the round. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.